Topical composition comprising an ophiopogon extract for use in the treatment of eyelids or the contour of the eye

Abstract

The invention relates to a topical composition comprising, as an active ingredient, a mixture of hyaluronic acid, trehalose and an extract of roots of Ophiopogon japonicus for use as a soothing agent and / or moisturizer for eyelids and / or the contour of the eye in a subject having a sensitive skin, in particular having blepharitis.

Description

TOPICAL COMPOSITION COMPRISING AN EXTRACT OF OPHIOPOGON FOR USE IN THE TREATMENT OF THE EYELIDS OR EYE CONTOUR Technical field

[0001] The present invention relates to the technical field of ophthalmology.

[0002] It relates more particularly to a topical composition which can be used as a soothing and / or moisturizing agent for the eyelids and / or the eye contour of a subject with sensitive skin, in particular skin with an atopic tendency, in particular the treatment of acute blepharitis or chronic blepharitis. Prior art

[0003] The upper and lower eyelids, as well as the eye contour, have specific histological, biological, and functional characteristics that make them extremely fragile and more sensitive than any other area of ​​the face. For example, with more than 10,000 blinks per day, the eyelids are extremely stressed. In addition, the eyelids, like the eye contour, are areas of the face with few sebaceous glands; they have a thin, weakly protective hydrolipidic film, resulting in a reduced barrier function.

[0004] It is estimated that one-third of the adult population has more vulnerable skin that reacts more strongly to its environment. This is the phenomenon of sensitive skin, which is defined as cutaneous hyperreactivity involving non-immunological mechanisms or a lowering of the skin's tolerance threshold to stimuli that are usually well tolerated. Skin sensitivity is not the same on all areas of the body. For example, symptoms may appear only on the face. The manifestations of this sensitivity are feelings of discomfort, tightness, feelings of heating, and tingling. Sensitive skin is often dry skin, which amplifies its sensitivity. As the skin's hydrolipidic film ( / .e., the skin's protective barrier) is defective, the skin is more vulnerable and reacts more strongly to its environment.

[0005] Blepharitis is one of the cutaneous manifestations of sensitive skin, particularly atopic-prone skin, which is an attack chronic inflammatory skin disease with various origins. This skin sensitivity is also responsible for atopic dermatitis (or dermatitis), contact dermatitis, contact eczema, psoriasis and seborrheic dermatitis.

[0006] Blepharitis is an inflammation of the eyelids. There are many causes. They can be due to a dysfunction of the Meibomian glands, the oxidation of meibum lipids, oxidative stress in keratinocytes and skin fibroblasts, or even changes in the protective microbial biofilm. The causes can also be of environmental origin, particularly the sensitivity of the eyelids to natural light, blue light, as well as pollution. They can be acute and chronic.

[0007] - Acute blepharitis corresponds to sudden inflammatory flare-ups, appearing within 24 to 48 hours after a triggering event: infection, airborne allergens, pollution, untimely direct or indirect contact with cosmetic products (eye makeup or nail polish for example).

[0008] Blepharitis becomes chronic when the patient has to deal with acute recurrences. The challenge is then to space out recurrences as much as possible and to reduce the sensations of discomfort and inflammation between attacks.

[0009] Chronic blepharitis can also be the consequence of specific medical eye treatment, in particular treatment for glaucoma, or treatment for retinal diseases such as age-related macular degeneration or diabetic macular edema.

[0010] As mentioned previously, blepharitis generates different phenomena such as inflammation, but also pruritus, secondary dryness, eyelid superinfection or even bacterial proliferation.

[0011] Inflammation can manifest itself in various ways, such as a thickened eyelid margin, redness, a burning sensation, a feeling of heavy and swollen eyelids, and evening itching.

[0012] Secondary dryness can cause discomfort, peeling of the eyelids and also the appearance of crusts in the eyelashes.

[0013] We also observe a frequent chronicity of blepharitis, thus opening the way to two types of treatment: curative treatments aimed at stopping the signs of acute blepharitis and treatments acting on the chronicity of blepharitis, with the aim of spacing out recurrences.

[0014] The treatment of blepharitis is based on dermocorticoids, which have the disadvantage of causing addiction.

[0015] The objective is therefore to offer effective eyelid (lower and upper) and / or eye contour care that is capable of: - calm feelings of discomfort and inflammation, reduce itching, - restore the anti-evaporative functions of the mebomian secretions, - effectively and lastingly soothe the eyelids and the eye contour, - lastingly moisturize the eyelids and the eye contour, - heal weakened eyelids and the eye contour, - restore the barrier function of the skin of the eye and the eye contour, - rebalance the microbiota by strengthening the natural defenses of the skin of the eye and the eye contour and by limiting bacterial proliferation, - limit the use of dermocorticoids.

[0016] WO 2017 / 091916 describes a topical composition for the skin comprising a glycerol production promoter obtained from Staphylococcus epidermidis or keratinocytes. Trehalose, hyaluronic acid, and ADResyl (extract from the roots of Ophiopogon japonicus) are all described as optional additives to the composition, each in a list comprising numerous compounds.

[0017] CN 107693443 describes a lyophilized powder intended to be mixed with a solvent at the time of application to activate ocular energy. The powder contains numerous constituents, including trehalose, hyaluronic acid, and ADResyl. The mixture is intended to be used in combination with yoga practice to reduce the effect of under-eye bags, wrinkles, etc.

[0018] To the Applicant's knowledge, no treatment fulfilling all of the aforementioned objectives for the treatment of the eyelids and the eye contour of a subject with sensitive skin, in particular skin with atopic tendency, in In particular, the treatment of acute and chronic blepharitis has not been developed to date. Statement of the invention

[0019] One of the aims of the invention is therefore to propose a composition for use as a soothing and / or moisturizing agent, or in the soothing and / or moisturizing treatment of the eyelids and / or the eye contour of a subject with sensitive skin, in particular skin with an atopic tendency, in particular blepharitis, which makes it possible to stop the effects of this skin sensitivity, and in particular acute blepharitis, and which is capable of spacing out acute recurrences, characterizing chronic blepharitis.

[0020] In other words, the aim of the invention is to develop a composition for the eyelids and / or the eye contour capable of leading to a reduction, or even elimination, of sensations linked to sensitive skin syndrome, i.e. itching, tingling, discomfort, tingling, irritation, scratching, sensations of heat, or even burning. In addition, the reduction in itching and scratching will limit, or even eliminate, the appearance of lesions and / or the spread of pathogens and therefore contamination of the skin.

[0021] Another aim of the invention is to provide a composition for use as a soothing and / or moisturizing agent, or in the soothing and / or moisturizing treatment of the eyelids and / or the eye contour of a subject with sensitive skin, in particular skin with atopic tendency, in particular blepharitis, which, where appropriate, complements corticosteroid treatment, so as to limit the doses of standard active ingredients used in these pathologies.

[0022] The Applicant has demonstrated that the combination of a mixture of hyaluronic acid, trehalose and an extract of Ophiopogon japonicus roots was effective for use as a soothing and / or moisturizing agent, or in the soothing and / or moisturizing treatment of the eyelids and / or the eye contour of a subject with sensitive skin, in particular skin with atopic tendency, in particular acute blepharitis, and that the addition to this mixture of bakuchiol, an extract of the ferment of the microorganism Exiguobacterium sp and a vitamin E derivative made it possible to act on its chronicity.

[0023] The Applicant has demonstrated that the combination of a mixture of hyaluronic acid, trehalose and an extract of Ophiopogon japonicus roots was effective as a soothing and / or moisturizing agent for the eyelids and / or the eye contour of a subject with sensitive skin, in particular skin with atopic tendencies, in particular acute blepharitis, and that the addition to this mixture of bakuchiol, an extract of the ferment of the microorganism Exiguobacterium sp and a vitamin E derivative made it possible to act on its chronicity.

[0024] More specifically, the Applicant demonstrated that, taken separately, a mixture of hyaluronic acid and trehalose on the one hand and an extract of Ophiopogon japonicus roots on the other hand had an anti-inflammatory effect on the eyelids and / or the eye contour and that, in addition and above all, the combination of these 3 elements had a superior effect on inflammation, justifying the existence of an unexpected synergy between the different elements.

[0025] In other words and according to a first characteristic, the invention relates to a topical composition comprising, as active ingredient, a mixture of hyaluronic acid, trehalose and an extract of Ophiopogon japonicus roots, for its use as a soothing and / or moisturizing agent for the eyelids and / or the eye contour in a subject with sensitive skin, in particular skin with atopic tendency, in particular blepharitis.

[0026] The Applicant noted that this combination provided an immediate effect on hydration, relieving and soothing feelings of discomfort, itching, irritation, and restoring the balance of the skin flora.

[0027] For the purposes of the invention, a soothing agent ensures a reduction, or even elimination, of skin discomfort by reducing, or even eliminating, irritation, tingling, or even itching.

[0028] For the purposes of the invention, a moisturizing agent has the effect of increasing the water content of the skin via several mechanisms such as the repair and / or lasting strengthening of the skin barrier or the supply and / or retention of water.

[0029] The effect is also long-lasting due to the restoration of the skin barrier, the reduction of eyelid edema associated with inflammation, the strengthening of natural defenses and the reestablishment of microbiotic homeostasis.

[0030] According to a first characteristic, the hyaluronic acid has an average molecular weight of between 100 kDa and 600 KDa, advantageously between 300 kDa and 450 KDa, preferably 300 kDa.

[0031] The selection of this specific molecular weight range allows for a hyaluronic acid that penetrates into the deep layers of the eyelid, thus hydrating all layers of the epidermis and also participating in the synthesis of natural hyaluronic acid by stimulating its production. This results in a stimulation of the antibacterial activity of the skin due to the release by the skin of [3 defensins 2.

[0032] In practice, hyaluronic acid represents between 0.01% and 1%, advantageously between 0.02% and 0.3% by weight of the composition.

[0033] In a preferred embodiment, and in particular when the composition is used with a curative aim, the hyaluronic acid represents between 0.1% and 0.2%, preferably 0.15% by weight of the composition.

[0034] Trehalose appears to contribute to the overall effect of the composition through its bioprotective properties, thus preserving the cells of the epidermis. In practice, trehalose represents between 1% and 5%, preferably 3% by weight of the composition.

[0035] According to an essential characteristic, the composition includes an extract of Ophiopogon japonicus roots.

[0036] The Applicant found that particularly advantageous results were obtained in the treatment of blepharitis, in combination with the other active ingredients, when the extract represented between 0.2% and 1% by weight of the composition.

[0037] In a preferred embodiment, and in particular when the composition is used with a curative aim, the extract of Ophiopogon japonicus roots advantageously represents between 0.4% and 0.5% by weight of the composition, advantageously 0.45%.

[0038] According to another feature, when the composition is used to limit the chronicity of blepharitis, it further comprises bakuchiol, a ferment extract of the microorganism Exiguobacterium sp. and a water-soluble derivative of vitamin E.

[0039] The basic composition thus completed helps restore the skin's barrier function and therefore ensures long-term treatment of chronic blepharitis. It also helps reduce itching and irritation and protects the eyelids from external aggressions. It also reduces the appearance of dark circles and puffiness.

[0040] Under these conditions, it contains between 0.04% and 0.06%, advantageously 0.05% by weight of hyaluronic acid and between 0.5% and 0.7%, advantageously 0.6% by weight of Ophiopogon japonicus root extract.

[0041] Bakuchiol is extracted from babchi seeds and has retinol-like functions. It regulates cell differentiation and stimulates collagen synthesis. It also acts as an antioxidant, maintains lipid homeostasis, and inhibits opportunistic bacterial proliferation.

[0042] In practice, bakuchiol represents between 0.5% and 1%, preferably 0.75% by weight of the composition.

[0043] According to the invention, the composition contains a ferment extract of the microorganism Exiguobacterium sp., advantageously the raw material corresponding to the INCI: glycerin (and) water (and) hydrolyzed pea protein and glucose and sodium chloride and sodium succinate.

[0044] This raw material is known in particular for protecting against light-related aggressions, aging (anti-blue shield) and hyperpigmentation (anti-dark circle effect). Here again, the Applicant had the idea of ​​applying these properties to the specific case of the eyelid, by combining this product with the other aforementioned ingredients with which synergy has been demonstrated.

[0045] In practice, the ferment extract of the microorganism Exiguobacterium sp. represents between 0.5% and 5%, preferably from 1.5% to 3% by weight of the composition.

[0046] For the treatment of recurrence, the composition also contains a water-soluble vitamin E derivative representing between 0.1% and 1%, preferably 0.5% by weight of the composition.

[0047] The vitamin E derivative is known for its effect on protection against UVA / UVB irradiation, its protective effect against oxidative inflammation induced by UV and pollution, its effect on increasing ceramic synthesis and finally its anti-dark circle effect.

[0048] The composition of the invention can be used where appropriate in combination with dermocorticoids, either simultaneously or successively with them.

[0049] In an advantageous embodiment, the composition of the invention is used in addition to treatment with dermocorticoids, after stopping them, in particular for the treatment of acute blepharitis.

[0050] In another embodiment, the composition of the invention is used alternately with treatment with dermocorticoids, for example application in the evening of one and application in the morning of the other, in particular for the treatment of acute blepharitis.

[0051] In another embodiment, the composition of the invention is used alternately with treatment with dermocorticoids, for example application of one in the evening and application of the other in the morning, then use alone after stopping the dermocorticoids, in particular for the treatment of acute blepharitis.

[0052] In another embodiment, the composition of the invention is used for the treatment of chronic blepharitis generated in the context of the treatment of an ocular disease, such as for example glaucoma, age-related macular degeneration, diabetic macular edema, in the absence or in addition to dermocorticoids. Brief description of the drawings

[0053] Other advantages and characteristics of the invention will emerge more clearly from the following description, given by way of non-limiting example, of the composition according to the invention, from the appended drawings in which:

[0054] [Fig. 1] is a curve representing the evolution of the percentage of HBD2 ([3 defensin 2) as a function of time after the application of different compositions on the eyelids following an induction of inflammation by injection of LPS (lipopolysaccharide).

[0055] [Fig. 2] is a curve representing the evolution of the daily self-assessment of itching, during the 28 days of application of the composition of the invention, by means of a score for itching ranging from 0 (no itching) to 10 (severe itching). Detailed description of the invention

[0056] Study of the anti-inflammatory effect of the composition of the invention on the eyelid in the case of curative treatment (acute blepharitis) by dosage of HBD2.

[0057] The list of ingredients used in the tested compositions is shown in Table 1.

[0058] [Table 1]: C059] From these ingredients, three solutions were made: Solution 1: Primalhyal-Trehalose: mixture of 0.15% Primalhyal 300 and 3% Trehalose 100. Solution 2: ADResyl: solution containing 0.45% ADResyl Solution 3 (composition of the invention): solution 1 + solution 2. The solutions were made in distilled water.

[0060] The anti-inflammatory effect of the different solutions is observed by the ex vivo cutaneous microdialysis technique on fresh eyelids. The principle of this technique is to insert into the dermis, a sterile microprobe equipped at its end with a semi-permeable membrane continuously perfused by a sterile physiological liquid. This membrane allows, by concentration gradient, to analyze the dermal interstitial fluid, whether for endogenous compounds or for exogenous compounds.

[0061] Three eyelids are collected and placed in an antibiotic bath in the form of a 10% Penicillin-Streptomycin and 10% Amphotericin B solution for 15 minutes. The samples are then dried using absorbent paper. A microdialysis probe is inserted into the dermis of each eyelid using a probe guide. The eyelids are placed in survival medium on a heating plate. An hour is allowed to stabilize the eyelids following insertion of the probe. A physiological solution (Ringer) is then infused at 3 pL / min. The microdialysates are collected for 1 hour to obtain a basal value (T0) of HBD-2. Induction of inflammation is achieved by back-injection of 0.8 mg / ml of LPS intradermally (12.5 μl on each side of the probe) and the compositions are applied to the surface of the eyelids.Samples are taken every hour for 6 hours. The microdialysates are stored at -20°C until HBD2 is measured using an ELISA kit.

[0062] The HBD-2 in the samples binds specifically to the antibodies coated at the bottom of the wells. The development is carried out using a streptavidin-HRP solution and chromogen solutions that will cause a blue color development. The intensity of the color is directly proportional to the amount of HBD-2 in the wells.

[0063] 50 μl of standard (from 0 to 500 pg / ml of HBD-2) and 50 μl of microdialysate are placed in the wells of a 96-well plate with 100 μl of HRP-streptavidin. The plate is incubated for 1 h at 37°C. After a series of washes, two different chromogen solutions are added to the wells and the plate is incubated for 15 min at 37°C. The color reaction is stopped by the addition of 50 μl of H2SO4. The plate is immediately read at 450 nm (Thermo Multiskan FC). The fluorescence intensity is proportional to the amount of HBD-2 present in the samples and standards. The calibration range allows the determination of HBD-2 concentrations in the samples. The results are expressed as a percentage of HBD-2 relative to T6 (6 h).

[0064] The results are shown in Figure 1.

[0065] Solution 3 corresponding to the composition of the invention has an effective anti-inflammatory effect for the curative treatment of acute blepharitis induced in the present model, by injection of LPS. Indeed, when a comparison is made with solution 1 (Primalhyal + Trehalose) and solution 2 (ADResyl alone), solution 3 very significantly reduces inflammation compared to solutions 1 and 2.

[0066] In vivo study of the effect of the composition of the invention in patients with acute blepharitis (curative treatment)

[0067] Composition 1 is prepared, the formula of which is shown in Table 2.

[0068] [Table 2]:

[0069] Patient 1 Profile : 24-year-old woman with atopic blepharitis with edematous reaction of the eyelids.

[0070] Protocol: Treatment: dermocorticoid in the evening and composition 1 applied to the eyelids Morning Stop the dermocorticoid on the 3rd èmeday and continuation of treatment with only composition 1 in the morning Observations: Disappearance of the burning sensation at 2 ème day Disappearance of edema from the 3rd ème day Control 5 ème day: on examination, no desquamation

[0071] Patient 2 Profile : 18-year-old woman with eyeshadow contact dermatitis, edematous and pruritic blepharitis Protocol: Treatment: dermocorticoid in the evening and composition 1 applied to the eyelids in the morning Observations: Feeling of calm and comfort from the first application of the composition 1. More than 90% reduction in edema on the 3rd ème day 5th day check: - Edema almost gone - Discreet furfural desquamation

[0072] Patient 3 Profile : 50-year-old man: contact dermatitis with onctosis, unilateral edematous blepharitis evolving for more than 48 hours without signs of shingles Protocol: Treatment: dermocorticoid in the evening + composition 1 applied to the eyelids in the morning Stop corticosteroids after 48 hours + continue treatment with the composition 1 morning and evening Observations: Almost immediate disappearance of burning sensations Immediate and lasting feeling of comfort Significant improvement in 48 hours Decreased edema at 3 ème day Near-normal appearance of the affected eyelid at 5 ème day

[0073] Patient 4 Profile : 15-year-old boy: blepharitis of both eyelids as a result of contact eczema. Protocol: Right eye: Dermocorticoid in the evening and Eczeane® UHT in the morning Left eye: Dermocorticoid in the evening and composition 1 in the morning Observations: Right eye: continued dermocorticoid at 5 ème day Left eye: marked improvement in 3 ème day with stopping the dermocorticoid and maintaining composition 1 only.

[0074] Conclusion The above results show that the composition of the invention can replace dermocorticoids or complement them during treatment.

[0075] In vivo study of the effect of the composition of the invention in patients with chronic blepharitis (chronic treatment)

[0076] Composition 2 is prepared, the formula of which is shown in Table 3.

[0077] [Table 3]:

[0078] Patient 1 Profile : 62-year-old woman: on anti-glaucoma treatment (1 drop / day) with chronic blepharitis resulting from the treatment. The signs of chronic blepharitis are characterized by fine desquamation and accentuation of fine lines of the external cantus, sensation of skin discomfort with difficulty applying makeup. Protocol: Morning and evening application of composition 2 Observations: io control ème day : - Feeling of comfort and calm - The eyelids appear better hydrated to the patient - Disappearance of redness - Ease of makeup - On clinical examination, the eyelids are less red, less wrinkled, there is no more desquamation Control at 30 ème day : - The patient confirms the subjective sensations observed on the 10th day with a clear improvement in eyelid comfort - Tolerance is perfect - A lighter appearance of the eyelids is noted by the patient Control at 3 ème month : - The patient confirms the qualities of the product - She no longer suffers from blepharitis - Her fine lines are clearly reduced - The skin is significantly lighter

[0079] Patient 2 Profile : 72-year-old woman: on anti-glaucoma treatment for 3 years (1 drop / day) with chronic blepharitis resulting from the treatment. The signs of chronic blepharitis are characterized by redness and scaling, and a feeling of discomfort. Blepharitis is treated with a course of dermocorticoids. Protocol: Morning and evening application of composition 2 and stopping the dermocorticoid Observations: Control at 30 ème day : The feelings of irritation have diminished The patient feels significantly more comfortable than before. On examination, the skin is less wrinkled, more toned and appears clearer, which is confirmed by the patient.

[0080] Patient 3 Profile : 58-year-old woman: on anti-glaucoma treatment for 5 years (1 drop / day) with erythematous and pigmentogenic blepharitis. Chronic discomfort with itchy flushes. Use of topical corticosteroids on demand despite contraindication. Protocol: Stopping dermocorticoids Morning and evening application of composition 2 Observations: Control at 30 ème day : - Rapid disappearance of itching sensations, in 1 week - Eyelid comfort restored - Feeling of well-hydrated eyelids - Less visible pigmentation

[0081] Patient 4 Profile : Man, 38 years old: Atopic erythroderma, chronic blepharitis with lichen-like appearance of the eyelids, disabling pruritus. Protocol: Placed on dupilumab, which is a human monoclonal antibody targeting interleukins 4 and 13 and aimed at controlling atopic erythroderma after failure of other systemic treatments. Also placed on emollient, face and body Application of composition 2 morning and evening for 1 month on the eyelids. Observations: Control at 30 ème day : The patient says he feels a sense of relief and suppleness in his eyelids at 10 ème day This feeling continues and amplifies in the 20th ème and 30 ème day The eyelids are less cardboardy and itch much less Blinking is no longer painful On examination, the eyelids are more supple, clearer, better hydrated. The effect is clearly superior to previous applications of conventional emollients. The patient, who is very focused on his eyelids, describes a very clear improvement. For 1 month, he no longer feels the need to use dermocorticoids on his eyelids. Product fault at 6 ème week, he is led to resume his classic emollient 10-week check-up: The eyelid discomfort has reappeared The general condition is improved but the eyelid function is again degraded. The patient reuses a dermocorticoid twice a week on the eyelids and face.

[0082] Conclusion Observations show that the use of the composition of the invention gives effective and rapid results on chronic blepharitis, in particular with regard to redness, signs of desquamation, and the feeling of discomfort, in the absence or in addition to dermocorticoids.

[0083] In vivo study of the effect of the composition of the invention in patients with sensitive skin Composition 1 is prepared, the formula of which is shown in Table 2.

[0084] Population / Profile: Men and women aged 18 and over, all with sensitive skin ( / .e., sensitive skin) around the eyelids and around the eyes. This sensitive skin results in very dry skin that is then sensitive, irritated (itchy) and causes discomfort in the subject.

[0085] Protocol: Apply composition 1 (or 2) morning and evening to the entire eyelids and eye contour. Observations: Control 10 minutes (Dt10) after application and / or 28 days (Dj28) from the start of use of the composition of the invention of the itching, irritation and discomfort scores allowing to decide on the soothing, or even moisturizing, effect of the composition of the invention.

[0086] Results : The results are shown in Table 4 and Figure 2.

[0087] [Table 4]

[0088] Conclusion: The results show that the use of the composition of the invention soothes, in particular soothes and moisturizes, effectively the skin of the eyelids and the eye contour of subjects with sensitive skin, in the absence of dermocorticoids. This effect is observed in the very short term (+ 10 minutes) and in the medium / long term (+ 28 days), with a rapid and lasting reduction in itching sensations (figure 2) throughout the duration of use of the composition of the invention.

Claims

Demands [Claims 1] Topical composition comprising, as active ingredient, a mixture of hyaluronic acid, trehalose and an extract of Ophiopogon japonicus roots, said composition being for use as a soothing agent for the eyelids and / or the eye contour of a subject with sensitive skin. [Claims 2] Composition for its use according to claim 1, characterized in that the subject has atopic-prone skin. [Claims 3] Composition for its use according to claim 1 or 2, characterized in that the subject presents with blepharitis. [Claims 4] Composition for its use according to any one of the preceding claims, characterized in that the hyaluronic acid has an average molecular weight between 100 kDa and 450 kDa, preferably 300 kDa. [Claims 5] Composition for its use according to claim 4, characterized in that hyaluronic acid represents between 0.01% and 1%, advantageously between 0.02% and 0.3% by weight of the composition. [Claims 6] Composition for its use according to claim 5, characterized in that hyaluronic acid represents between 0.1% and 0.2%, preferably 0.15% by weight of the composition. [Claims 7] Composition for its use according to any one of the preceding claims, characterized in that trehalose represents between 1% and 5%, preferably 3% by weight of the composition. [Claims 8] Composition for its use according to any one of the preceding claims, characterized in that the extract of Ophiopogon japonicus roots represents between 0.2% and 1% by weight of the composition. [Claims 9] Composition for its use according to claim 8, characterized in that the extract of Ophiopogon japonicus roots represents between 0.4% and 0.5% by weight of the composition, advantageously 0.45%. [Claims 10] Composition for its use according to any one of claims 3 to 9, characterized in that the blepharitis is acute blepharitis. [Claims 11] Composition for its use according to any one of the preceding claims, characterized in that it further comprises bakuchiol, a ferment extract of the microorganism Exiguobacterium sp. and a water-soluble derivative of vitamin E. [Claims 12] Composition for its use according to claim 11, characterized in that it contains between 0.04% and 0.06%, advantageously 0.05% by weight of hyaluronic acid, and between 0.5% and 0.7%, advantageously 0.6% by weight of Ophiopogon japonicus root extract. [Claims 13] Composition for its use according to any one of claims 11 or 12, characterized in that bakuchiol represents between 0.5% and 1%, preferably 0.75% by weight of the composition. [Claims 14] Composition for its use according to any one of claims 11 to 13, characterized in that the ferment extract of the microorganism Exiguobacterium sp. corresponds to the INCI name glycerin (and) water (and) hydrolyzed pea protein and glucose and sodium chloride and sodium succinate. [Claims 15] Composition for its use according to claim 14, characterized in that glycerin (and) water (and) hydrolyzed pea protein and glucose and sodium chloride and sodium succinate represents between 0.5% and 5%, preferably from 1.5% to 3% by weight of the composition. [Claims 16] Composition for its use according to any one of claims 11 to 15, characterized in that the water-soluble derivative of vitamin E represents between 0.1% and 1%, preferably 0.5% by weight of the composition. [Claims 17] Composition for its use according to any one of claims 11 to 16, characterized in that the blepharitis is chronic blepharitis. [Claims 18] Composition for its use according to claim 10, characterized in that it is used as an adjunct to treatment with dermocorticoids, after stopping the latter or in alternation with treatment with dermocorticoids. [Claims 19] Composition according to any one of claims 11 to 17, for use in the treatment of an eye disease, in the absence or in addition to dermocorticoids.

Images